On July 9, Nanjing Jiangbei New Area signed a comprehensive strategic cooperation agreement with Bristol Myers Squibb (herein after referred to as BMS), a global famous biopharmaceutical company. Han liming, member of the Standing Committee of Jiangsu Provincial Party Committee and Secretary of Nanjing Municipal Party Committee, Luo Qun, member of the Standing Committee of CPC Nanjing Municipal Party committee and Full-time Deputy Secretary of the Party Working Committee of Jiangbei New Area, Jiang Yuejian, member of the Standing Committee and Secretary General of Nanjing Municipal Party Committee, Cai Xuejun, global vice president of Bristol Myers Squibb attended the event.
At present, Nanjing is making every effort to build a new landmark of new pharmaceutical and life health industry. In recent years, focusing on the construction of "Gene city", Jiangbei New Area has built an industrial scale of 100 billion RMB level in terms of life and health industry cluster, and made efforts to build a new pharmaceutical R & D highland with gene and cell technology as the core engine in advance.
Luo Qun said that in the past six years since its establishment, Jiangbei New Area has rapidly gathered a large number of top innovation resources, such as Cambridge University Science and Technology innovation center, a large number of high-level talents, also a large number of Unicorn high-tech and gazelle enterprises, which makes contributions to its international orientation of city and creating a good innovation ecology. Innovation has becomes a resounding business card of the new area. The life and health industry of Jiangbei New Area has constructed the whole industry chain of big health. At present, more than 900 upstream and downstream enterprises of big health industry have gathered, and the industrial scale has reached 100 billion RMB, showing strong innovation ability and development potential. Bristol Myers Squibb has chosen Nanjing Jiangbei New Area as the partner, which will help the biomedical enterprises in Nanjing and Jiangbei New Area to graft the cooperation bridge with overseas scientific research resources in the fields of chemical agents, biological agents and cell therapy, and promote the development of scientific and technological projects, incubation of high-quality projects and landing of innovative projects in the new area.
Dr. Cai Xuejun said that under the guidance of Bristol Myers Squibb's "China strategy 2030", we are committed to promoting the life and healthy industry in an orderly way through more extensive and diversified cooperation with the local actual situation. The strategic cooperation with Nanjing Jiangbei New Area is a new chapter for us to fulfill this commitment, which is to help promote the cooperation in the establishment of research hospital alliance in the new era, the application of real world’s big data, and the cultivation of R & D talents, and to promote the new ecology of innovative research of life science in the Yangtze River Delta.
At the event, Luo Qun awarded Dr. Cai Xuejun a letter of appointment as a scientist of Gene and Cell Laboratory in Jiangbei New Area. Previously, Gene and Cell Laboratory has employed eight scientists and industry experts, including Shen Hongbing, academician of Chinese Academy of Engineering, Huang He, President of the First Affiliated Hospital of Medical College of Zhejiang University. It is believed that Dr. Cai Xuejun's participation will further enhance the talent strength and international cooperation level of the Scientific Committee.
This opening ceremony also marks the formal establishment of the strategic cooperation alliance of research hospitals established by key medical institutions in Jiangsu Province. As the advocate of the alliance, Bristol Myers Squibb will provide technical guidance and suggestions for the city to absorb innovative clinical research projects, improve the level of drug clinical trials and expand international cooperation channels in clinical research. The alliance is an open alliance. In the next stage, it will further attract medical institutions in Nanjing city and innovative life science enterprises at home and abroad to join together, promote clinical research of innovative products, and provide more medical options for Chinese patients as soon as possible.
Jiangbei New Area signed a comprehensive strategic cooperation agreement with Bristol Myers Squibb and a joint project cooperation agreement with Gene and Cell Laboratory, which means the global R & D cooperation project between Jiangbei New Area and Bristol Myers Squibb was officially launched. Through comprehensive strategic cooperation, the two sides will deepen exchanges, fully tap and give play to the advantages of cutting-edge innovation resources, promote the development of science and technology projects, incubation of high-quality projects and landing of innovation projects, and help the high-quality construction of new pharmaceuticals and life health industry chain in Nanjing.